PAIO.F Stock Overview
A specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Paion AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.02 |
52 Week High | €0.07 |
52 Week Low | €0.02 |
Beta | 1.61 |
11 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | n/a |
33 Year Change | -99.90% |
5 Year Change | -99.91% |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
PAIO.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 4.0% | 2.2% |
1Y | n/a | 18.3% | 32.6% |
Return vs Industry: Insufficient data to determine how PAIO.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PAIO.F performed against the US Market.
Price Volatility
PAIO.F volatility | |
---|---|
PAIO.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PAIO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PAIO.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 64 | Gregor Siebert | www.paion.com |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
Paion AG Fundamentals Summary
PAIO.F fundamental statistics | |
---|---|
Market cap | US$46.33k |
Earnings (TTM) | -US$20.80m |
Revenue (TTM) | US$15.51m |
0.0x
P/S Ratio0.0x
P/E RatioIs PAIO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PAIO.F income statement (TTM) | |
---|---|
Revenue | €14.81m |
Cost of Revenue | €6.35m |
Gross Profit | €8.46m |
Other Expenses | €28.32m |
Earnings | -€19.86m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.78 |
Gross Margin | 57.15% |
Net Profit Margin | -134.12% |
Debt/Equity Ratio | -675.5% |
How did PAIO.F perform over the long term?
See historical performance and comparison